Beverley Moore: Lawyer with Borden Ladner Gervais LLP

Beverley Moore

Ottawa,  ON  Canada

Peer Rating

Client Rating

Printer Friendly VersionEmail this PageDownload to My Outlook ContactsAdd lawyer to My FavoritesCompare this lawyer to other lawyers in your favorites

Experience & Credentials

Practice Areas

  • Intellectual Property
  • Life Sciences
  • Appeal and Review
  • Intellectual Property Litigation
  • Privacy and Data Security
  • Healthcare Intellectual Property Protection and Commercialization
  • Patents
University Queen's University, B.Sc., Hons. in Biochemistry, 1997; Queen's University, M.Sc. in Biochemistry, 2000
Law SchoolQueen's University, LL.B., 2002
Admitted2003, Ontario

Professional Involvement

•Member, BIOTECanada's Health Advisory Board and Subsequent Entry Biologics Task Force
•Member, Intellectual Property Institute of Canada (IPIC), IPIC Editorial Board for the Canadian Intellectual Property Review, IPIC Competition Law and IPIC International Patents Committees
•Member, Intellectual Property Owners Association (IPO), IPO Patent Law and Practice (International) Committee
•Member, American Bar Association (ABA), IP Section and the ABA Committees on Patents in the Chemical & Life Sciences and International Patent Treaties & Laws
•Member, Canadian Bar Association (CBA), American Intellectual Property Law Association (AIPLA) and County of Carleton Law Association (CCLA)


Beverley Moore practises intellectual property litigation at Borden Ladner Gervais LLP, focusing on patent litigation and applications under the Patented Medicines (Notice of Compliance) Regulations (NOC Regulations). She also advises clients on regulatory issues such as listing patents on the Patent Register, reporting patents to the Patented Medicines Prices Review Board (PMPRB), and the Register of Innovative Drugs as it relates to data protection. Beverley also advises on Access to Information (ATI) requests, in particular those made to Health Canada by pharmaceutical clients. In addition, Beverley advises on patent portfolio management, patentability, validity and freedom-to-operate issues, and aids in the prosecution of patent applications in Canada.

Beverley sits on the editorial board of the Canadian Intellectual Property Review, and is a co-editor of Carswell's Consolidated Intellectual Property Statutes and Regulations, and co-author of the book's “Patents - Year in Review” article. Beverley and her colleagues, Chantal Saunders and Adrian Howard, publish a weekly IP Bulletin, summarizing recent IP cases and industry news of note. In addition, Beverley is a member of BIOTECanada's Health Advisory Board and Subsequent Entry Biologics Task Force, and has participated in National Advocacy Day, lobbying politicians on biotechnology issues. Beverley's M.Sc. research involved mechanistic studies with Vitamin D analogues.

Publications & Presentations

•Co-Editor, Consolidated Intellectual Property Statues and Regulations with Related Materials, 2012-present.
•Contributing Author & Co-Editor, BLG's Intellectual Property Weekly Abstracts Bulletin.
•Contributing Author, Life Sciences & Chemical Patent Practice in Canada: A Practical Guide, 3rd edition, Borden Ladner Gervais LLP, 2011, available free of charge at .
•Co-Author, Court Guidance Needed Under Sound Prediction Doctrine, Drug Development & Outsourcing Guide 2015, Contact Canada.
•Co-Author, Sound Prediction in Canada: The Promise is Still Important, Drug Development & Outsourcing Guide 2014, Contact Canada.
•Co-Author, “Supreme Court Issues Decision Discussing Test for Sufficiency of Disclosure in a Patent,” US and Canada Drug Development Guide and Canadian Biotechnology, January 2013.
•Co-Author “Invalidated Patents: Changes to case law creates uncertainty for biotechs. Just how sound do a patent's predictions need to be ” Bio Business, May/June 2012.
•Co-Author, “Patentability of Diagnostic Methods in the wake of,” Drug Development & Outsourcing Industry Guide 2012.
•Author, “Supreme Court Dismisses Appeal But Sets Out Disclosure Tests for ATI Requests,” Canadian Privacy Law Review, March 2012.
•Co-Author, “Canada Regulatory Regimes; Tips on Regulatory Issues,” Managing Intellectual Property, October 2011.
•Co-Author & Co-Presenter, “Clinical Trials and their Presence in Patent Cases,” Insights Clinical Trials in Canada, April 2011.
•Panellist, “A Product's Lifecycle from Innovation to Commercialization: The Patented Medicines (Notice of Compliance) Regulations, the Patent Act and Data Protection,” Life Sciences BC, March 2011.
•Co-Author, “Fitting Biologic Products into the Data Protection and Notice of Compliance Regulatory Schemes,” Canadian Biotechnology Industry Guide 2011, January 2011.
•Co-Author, “The Canadian Biotechnology Public Policy Agenda,” Biotechnology Focus, September 2011.
•Co-Author, “Sufficiency of Disclosure and Sound Prediction Requirements in Canada,” IPO Committee Newsletter, August 2011.
•Co-Author, “The Canadian Patent Register: Your Shield Against Premature Generic Competition,” Pharma & BioPharma Industry Guide, January 2011 .
•Panellist, “Exploiting New Opportunities in Biologics and Subsequent Entry Biologics: A Brief Discussion of Legal Issues Surrounding the Guidance Document Regarding Subsequent Entry Biologics,” 9th Annual Forum on Pharma Patents, November 2010.
•Co-Author, “Disclosure Requirements Increased,” Managing Intellectual Property, October 2010.
•Co-Author, “Update on Intellectual Property Protection for Biotechnology in Canada,” BIOTECanada Insights, Fall 2010.

Beverley occasionally blogs on the “ BLG Not-for-Profit and Charity Law in Canada Blog ”. This Blog is intended to be of value to anyone in Canada who has any involvement with Not-For-Profit Organizations or Charities.

Reported CasesRepresentative Work; Appearing before the Federal Court and the Federal Court of Appeal. Acting as counsel for innovative companies asserting validity and infringement of patents during proceedings brought pursuant to the NOC Regulations. Acting as counsel for innovative companies challenging and judicially reviewing the Minister of Health's refusal to list patents on the Patent Register. Acting as counsel for innovative companies defending generic companies' claims for damages pursuant to s. 8 of the NOC Regulations. Acting as counsel for innovative companies leading to the settlement of a patent infringement and validity proceedings involving claims to drugs and process to make them. Advising clients on patent portfolio issues relating to data protection, listing patents on the Patent Register and reporting to the PMPRB. Preparing freedom-to-operate, infringement and validity opinions with respect to intellectual property matters. Acting as counsel for clients seeking leave to intervene in proceedings before the Supreme Court of Canada.

Documents by this lawyer on

Subscribe to this feed

Data Protection Regulations Apply When Comparison Added After NDS Filed
Adrian J. Howard,Beverley Moore,Chantal Saunders, November 27, 2015
In this case, Hospira applied for judicial review of a decision of the Minister of Health, refusing to issue it a Notice of Compliance (NOC) for its drug oxaliplatin. The Minister had found that Hospira compared to Sanofi's innovative drug ELOXATIN oxaliplatin, and thus the data protection...

FCA Reinstates PMPRB Jurisdiction over Generic Companies with Permission from Patentee to Sell Medicine as they Enjoyed a Benefit from the Patent
Adrian J. Howard,Beverley Moore,Chantal Saunders, November 27, 2015
In these cases, the government appealed Federal Court decisions that allowed judicial reviews of multiple PMPRB decisions. The issue on appeal was whether the Federal Court Judge properly held that Sandoz and ratiopharm fell outside the jurisdiction of the PMPRB, as they were not...

Gilead Has Successfully Obtained a Declaration of Invalidity of a Patent that It Reasonably Expected Would Be Asserted Against It
Adrian J. Howard,Beverley Moore,Chantal Saunders, November 24, 2015
The Federal Court has allowed Gilead's claim to invalidate Idenix's ‘191 patent on the grounds of insufficient disclosure and lack of demonstrated utility/sound prediction. Idenix's counterclaim that Gilead's ‘657 Patent is invalid for anticipation was dismissed.

Profile Visibility
#159 in weekly profile views out of 3,330 lawyers in Ottawa, Ontario
#93,313 in weekly profile views out of 1,733,488 total lawyers Overall

Office Information

Beverley Moore

100 Queen Street, Suite 1100
OttawaON K1P 1J9


Professional Networking for Legal Professionals Only

Quickly and easily expand your professional
network - join the premier global network for legal professionals only. It's powered by the
Martindale-Hubbell database - over 1,000,000 lawyers strong.
Join Now